John Taylor, 69, from the Lake District, went to his GP twice complaining about needing to pass urine more than normal, but ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

In a significant advancement for prostate cancer research, a first-of-its-kind study led by Emory researchers uncovered how ...

Prostate cancer is the most prevalent cancer in Australia. This article discusses the limitations of PSA tests in determining prostate cancer and highlights new guidelines for better detection and ...

In the past, having metastatic castrate-resistant prostate cancer was like a death sentence with clinician not having much ...